Parand Darou Pharma Parand Darou Pharma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"RevolKa","sponsor":"La Jolla Institute for Immunology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"La Jolla Institute for Immunology and RevolKa Started a Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by RevolKa

    Menu

    RevolKa

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              RevolKa

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              La Jolla Institute for Immunology and RevolKa Started a Research Collaboration

              Details:

              The collaboration aims to create antigens for the next-generation vaccines, including RK009, to deliver innovative solutions to unmet medical need in infectious diseases.

              Lead Product(s): RK009

              Therapeutic Area: Infections and Infectious Diseases Product Name: RK009

              Highest Development Status: Discovery Product Type: Vaccine

              Partner/Sponsor/Collaborator: La Jolla Institute for Immunology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 18, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
              IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
              Post Enquiry
              POST ENQUIRY